DOI:
10.1055/s-00000059
Pneumologie
LinksClose Window
References
Goss G, Tsai CM, Shepherd FA. et al.
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.
Lancet Oncol 2016;
17: 1643-1652
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.